Efrat Dotan, MD

Department of Hematology/Oncology

This physician is not currently rated. Why?

This Fox Chase professor participates in the Undergraduate Summer Research Fellowship.
Learn more about Research Volunteering.

Request an Appointment

Call 888-369-2427

Request Online

Clinical Locations

Primary Location
Fox Chase Cancer Center

Chief, Division of Gastrointestinal Medical Oncology

Associate Professor, Department of Hematology/Oncology

Associate Director, Hematology/Oncology Fellowship Training Program

NCCN, Chair of the Older Adult Oncology Panel

NCCN, Pancreatic Adenocarcinoma Panel Member

Specialties

Treatment Focus

Gastrointestinal cancers; Geriatric Oncology

Research Program

Cancer Prevention and Control

Key Awards

Medical Oncology

Language(s) Other than English

Hebrew

Treatment Philosophy

I specialize in treatment of patients with gastrointestinal cancers with various chemotherapies. My goal is to provide each patient with cutting-age therapy for their cancer, and the supportive care necessary for tolerating treatment. I am specifically interested in caring for older adults with gastrointestinal cancers, while focusing on other factors that are not related to their cancer and complicate their care.

Follow on Twitter @efratdotan

Educational Background

Fellow & Chief Fellow, Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA
Resident & Chief Resident, Internal Medicine, Lenox Hill Hospital, New York, NY, 2007
Resident, Internal Medicine, Lenox Hill Hospital, New York, NY, 2006
MD, Technion, Israel Institute of Technology, Israel, 2002

Certifications

American Board of Internal Medicine
Board Certification in Hematology and Medical Oncology

Memberships

National Comprehensive Cancer Network (NCCN)
- Cancer-Related Fatigue Panel
- Occult Primary Panel
- Older Adult Oncology Panel
American Society of Clinical Oncology (ASCO)
International Society of Geriatric Oncology (SIOG)
Cancer and Aging Research Group (CARG)
Eastern Cooperative Oncology Group (ECOG)
American Medical Association (AMA)

Honors & Awards

AMGEN Fellowship Grant 2009;
American College of Physician (ACP): Associate Research Competition Award

Shelby Hurley

Breast Cancer

I remember lying on the operating table before surgery, worrying about what was going to happen next. My breast was trying to kill me but it had still been difficult to make the decision to undergo a mastectomy.

VIEW PATIENT STORY

Robert Evans

In August 2015, Robert Evans, 70, went to a local suburban Philadelphia hospital to have surgery for a ruptured bowl after experiencing extreme pain in his abdomen. During the surgery, doctors decided it was best to remove his appendix because it was enflamed and interfering with the procedure. This was a fairly routine procedure, and a cancer diagnosis was far from Robert’s mind. When Robert learned he had cancer of the appendix, he sought a second opinion at Fox Chase Cancer Center, where he later underwent surgery. "I was, and remain today, very impressed by Fox Chase," Robert said. "My stay there was unlike any other hospital stay I have had. The quietness was absolutely incredible, and it was a very calming environment. From the person cleaning my room to the top-level nurses and physicians, everyone was spectacular."

VIEW PATIENT STORY

Darryl Hall

Colorectal Cancer

When Darryl Hall was diagnosed with colon cancer, he was referred to a surgeon at a local hospital. After two colonoscopies and exploratory surgery, Darryl still felt he had no solid answers regarding his condition. He decided to seek a second opinion from a specialist at Fox Chase Cancer Center. Darryl had a completely different experience at Fox Chase, where he underwent surgery and chemotherapy. "I encourage other people like me to get a second opinion if they are not happy with their current treatment plan," he said. "Both my wife and I received the best of care at Fox Chase. We are grateful to our doctors, and we recommend Fox Chase to anyone needing cancer care. Today we are both doing well and can enjoy the time we spend together and with our five grandchildren."

VIEW PATIENT STORY

Research Interests

Clinical trials of novel treatments for gastrointestinal cancers.
Drug Development
Clinical trial specific to older cancer patients

Selected Publications

Seedor R.S., Meeker C.R., Lewis B., Handorf E.A., Filchner K.A., Varadarajan R., Hensold J., Padmanabhan A., Negin B., Blankstein K., Chawla N.R., Song W., Epstein J., Winn J., Goldstein L.J., Dotan E., Prospective comparison of geriatric assessment and provider's assessment of older adults with metastatic breast cancer in the community. Oncologist. 27(2): E133-E141, 2022. <Go to ISI>://WOS:000764264500011.

Winer A., Handorf E.,Dotan E., Dosing schedules of gemcitabine and nab-paclitaxel for older adults with metastatic pancreatic cancer. Jnci Cancer Spectrum. 5(5): pkab074, 2021.PMC8438244. https://www.ncbi.nlm.nih.gov/pubmed/34532641.

Dotan E. The Future of Geriatric Oncology Research: Moving Toward Interventions and Objective Biomarkers of Aging. JNCCN September 2021, 19(9):1111-1113. DOI

Vijayvergia N, Dotan E, Devarajan K, et al. Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: A Fox Chase Cancer Center Experience. J Geriatr Oncol. 2015; S1879-4068. [Epub ahead of print]. PubMed

Dotan E, Li T, Hall M, Meropol N, Beck R, Wong YN. Oncologists’ Response to New Data Regarding the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer. JOP. September 2014 10(5): 308-14. PubMed

McCleary N, Dotan E, Browner I. Refining Chemotherapy Approach for Older Patients with Colon Cancer. J Clin Oncol, August 2014; 32: 2570-2580. PubMed

Dotan E, Devarajan K, D’Silva JA, Beck A, Kloth D, Cohen J S, Denlinger C. Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies among older adults with metastatic colorectal cancer. Clinical Colorectal Cancer. September 2014; 13(3):192-8. PubMed

Dotan E, Meropol N, Zhu F, Bove B, Cai K, Godwin A, Golemis A, Astsaturov I, Cohen S. Increased Aurora kinase A gene copy number is associated with improved prognosis and response to chemotherapy in patients with metastatic colorectal cancer. British Journal of Cancer. 2012 Feb 14;106(4):748-55 PubMed

Dotan E, Browner I, Hurria A, Denlinger C: Challenges in the management of elderly patients with colon cancer. JNCCN February 2012, 10(2):213-24 PubMed

Dotan E, Meropol J N, Burtness B, Denlinger C et al. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as front line therapy for metastatic colorectal cancer. A Fox Chase Extramural Research Study. J Gastrointest Cancer, December 2012, 43(4), 562-569. PMCID: PMC340072 PubMed... Expand

Additional Publications

My NCBI

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.